1. Andrae, B., Kemetli, L., Sparén, P., et al. Screening-preventable cervical cancer risks: evidence from a nationwide audit in Sweden. J Natl Cancer Inst, 2008, 7, 100(9), p. 622–629.
2. European Centre for Disease Prevention and Control. Introduction of HPV vaccines in EU countries – an update. Stockholm: ECDC, 2012.
3. Katki, HA., Kinney, WK., Fetterman, B., et al. Cervical cancer risk for women undergoing concurrent testing for human papillomavirus and cervical cytology: a population-based study in routine clinical practice. Lancet Oncol, 2011, 12(7), p. 663–672.
4. Khan, MJ., Castle, PE., Lorincz, AT., et al. The elevated 10-years risk of cervical precancer and cancer in women with human papillomavirus (HPV) type 16 or 18 and the possible utility of type-specific HPV testing in clinical practice. J Natl Cancer Inst, 2005, 20, 97(14), p. 1072–1079.
5. Leyden, WA., Manos, MM., Geiger, AM., et al. Cervical cancer in women with comprehensive health care access: attributable factors in the screening process. J Natl Cancer Inst, 2005, 4, 97(9), p. 675–683.
6. Madzima, TR., Vahabi, M., Lofters, A. Emerging role of HPV self-sampling in cervical cancer screening for hard-to-reach women: Focused literature review. Can Fam Physician, 2017, 63(8), p. 597–601.
7. Quinn, M., Babb, P., Jones, J., Allen, E. Effect of screening on incidence of and mortality from cancer of cervix in England: evaluation based on routinely collected statistics. BMJ, 1999, 3, 318(7188), p. 904–908.
8. Whitlock, EP., Vesco, KK., Eder, M., et al. Liquid-based cytology and human papillomavirus testing to screen for cervical cancer: a systematic review for the U.S. Preventive Services Task Force. Ann Intern Med, 2011, 15, 155(10), p. 687–697, W214-5.
9. Wright, TC. Jr, Behrens, CM., Ranger-Moore, J., et al. Triaging HPV-positive women with p16/Ki-67 dual-stained cytology: Results from a sub-study nested into the ATHENA trial. Gynecol Oncol, 2017, 144(1), p. 51–56.
10. Wright, TC., Stoler, MH., Behrens, CM., et al. Primary cervical cancer screening with human papillomavirus: end of study results from the ATHENA study using HPV as the first-line screening test. Gynecol Oncol, 2015, 136(2), p. 189–197.